Literature DB >> 29076505

Therapy: SGLT inhibition in T1DM - definite benefit with manageable risk.

Ele Ferrannini1, Anna Solini2.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 29076505     DOI： 10.1038/nrendo.2017.139

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  10 in total

1.  Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors.

Authors:  Julio Rosenstock; Ele Ferrannini
Journal:  Diabetes Care       Date:  2015-09       Impact factor: 19.112

Review 2.  Sodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology.

Authors:  Ele Ferrannini
Journal:  Cell Metab       Date:  2017-05-11       Impact factor: 27.287

3.  Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry.

Authors:  Kellee M Miller; Nicole C Foster; Roy W Beck; Richard M Bergenstal; Stephanie N DuBose; Linda A DiMeglio; David M Maahs; William V Tamborlane
Journal:  Diabetes Care       Date:  2015-06       Impact factor: 19.112

4.  Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.

Authors:  Paresh Dandona; Chantal Mathieu; Moshe Phillip; Lars Hansen; Steven C Griffen; Diethelm Tschöpe; Fredrik Thorén; John Xu; Anna Maria Langkilde
Journal:  Lancet Diabetes Endocrinol       Date:  2017-09-14       Impact factor: 32.069

5.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS.

Authors:  Yehuda Handelsman; Robert R Henry; Zachary T Bloomgarden; Sam Dagogo-Jack; Ralph A DeFronzo; Daniel Einhorn; Ele Ferrannini; Vivian A Fonseca; Alan J Garber; George Grunberger; Derek LeRoith; Guillermo E Umpierrez; Matthew R Weir
Journal:  Endocr Pract       Date:  2016-06-01       Impact factor: 3.443

6.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

Review 7.  Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.

Authors:  Pablo Lapuerta; Brian Zambrowicz; Paul Strumph; Arthur Sands
Journal:  Diab Vasc Dis Res       Date:  2015-03       Impact factor: 3.291

8.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Authors:  Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews
Journal:  N Engl J Med       Date:  2017-06-12       Impact factor: 91.245

9.  Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.

Authors:  Satish K Garg; Robert R Henry; Phillip Banks; John B Buse; Melanie J Davies; Gregory R Fulcher; Paolo Pozzilli; Diane Gesty-Palmer; Pablo Lapuerta; Rafael Simó; Thomas Danne; Darren K McGuire; Jake A Kushner; Anne Peters; Paul Strumph
Journal:  N Engl J Med       Date:  2017-09-13       Impact factor: 91.245

10.  Use of Adjuvant Pharmacotherapy in Type 1 Diabetes: International Comparison of 49,996 Individuals in the Prospective Diabetes Follow-up and T1D Exchange Registries.

Authors:  Sarah K Lyons; Julia M Hermann; Kellee M Miller; Sabine E Hofer; Nicole C Foster; Birgit M Rami-Merhar; Grazia Aleppo; Jochen Seufert; Linda A DiMeglio; Thomas Danne; David M Maahs; Reinhard W Holl
Journal:  Diabetes Care       Date:  2017-08-02       Impact factor: 19.112
  10 in total
  2 in total

Review 1.  SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks.

Authors:  Simeon I Taylor; Jenny E Blau; Kristina I Rother; Amber L Beitelshees
Journal:  Lancet Diabetes Endocrinol       Date:  2019-10-01       Impact factor: 32.069

2.  A comparison of sotagliflozin therapy for diabetes mellitus between week 24 with week 52 : A protocol for mixed treatment comparisons meta-analysis.

Authors:  Nie Zhang; Zhi-Qun Gu; Yun-Long Ding; Liu Yang; Mao-Bing Chen; Qi-Han Zheng
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.